bcrp - publications

Predict more bcrp - ligand interactions now!

1. Anticancer Res. 2011 Dec;31(12):4491-500.

The cancer stem cell antigens CD133, BCRP1/ABCG2 and CD117/c-KIT are not
associated with prognosis in resected early-stage non-small cell lung cancer.

Herpel E, Jensen K, Muley T, Warth A, Schnabel PA, Meister M, Herth FJ, Dienemann
H, Thomas M, Gottschling S.

Institute of Pathology, University of Heidelberg, Heidelberg, Germany.

BACKGROUND: In various tumor entities, expression of cancer stem cell (CSC)
antigens has been proven to be prognostically unfavorable. However, for lung
cancer, the data are scant and conflicting.
PATIENTS AND METHODS: The CSC antigens CD117/c-KIT, CD133 and breast cancer
resistance protein-1 (BCRP1/ABCG2) were immunohistochemically analyzed in tissues
from a total of 133 completely resected stage I/II non-small cell lung cancer
(NSCLC) patients with a median follow-up time of 53.8 months. Their expression
was related to clinicopathological characteristics, angiogenic features and
RESULTS: Cox proportional hazards regression analysis revealed no association
between CSC antigens, disease-free survival or overall survival (OS). However, in
the subgroup of patients with relapse and tumors >3 cm, there was a trend towards
worse OS upon expression of CD117 (hazard ratio=2.6, 95%, confidence
interval=0.8-8.3, p=0.080). Except for CD133, which was overrepresented in T1
tumors (p=0.001), the CSC antigens were not linked to clinico-pathological
characteristics or angiogenic features.
CONCLUSION: In resected early-stage NSCLC, CSC antigens show no association with
prognosis. However, in patients with relapse and tumors >3 cm, expression of
CD117 might predict worse OS.

PMID: 22199321 [PubMed - in process]